Profile: Aptorum Group Ltd (APM.OQ)
21 Sep 2020
Aptorum Group Limited is preclinical stage pharmaceutical company. The Company is engaged in developing and commercializing a broad range of therapeutic, diagnostic technologies and product candidates. The Company is pursuing therapeutic and diagnostic projects in neurology, infectious diseases, gastroenterology, oncology and other disease areas. The Company is operated through Aptorum’s wholly-owned subsidiary, Aptorum Therapeutics Limited. The Company operates in two segments: Therapeutics Segment and Non-Therapeutic Segment. The Company’s product leading candidate are: ALS-1, ALS-4 and NLS-1.
Its Therapeutics segment is seeking to develop various drug molecules and certain technologies for the treatment and diagnosis of human disease conditions in neurology, infectious diseases, gastroenterology, oncology and other disease areas. It is also seeking to identify additional prospects to qualify for potential orphan drug designation, which address other current unmet medical needs.
The non-therapeutics segment encompasses two businesses: the development of surgical robotics and medical devices; and AML Clinic. The development of surgical robotics and medical devices business is operated through Signate Life Sciences Limited, a subsidiary of Aptorum Therapeutics Limited. The outpatient clinic is operated through its subsidiary, Aptorum Medical Limited.
ALS-1: Small molecule intended for the treatment of viral infections caused by Influenza virus A
ALS-1 is a small drug molecule which targets viral nucleoprotein (NP) and triggers the aggregation of NP, which prevents the aggregated NP from entering the nucleus. ALS-1 is designed to target a broad range of NP variants. It is also exploring ALS-1 as a potential treatment for viral infections caused by Influenza virus A. It is at the Lead Optimization Stage to optimize its drug-like properties.
ALS-4: Small molecule for the treatment of bacterial infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)
ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the colonization and survival of the bacterium in the body or that cause damage to the body’s systems. ALS-4 is under active development for the treatment of bacterial infections caused by Staphylococcus aureus including MRSA.
NLS-1: A Derivative of Epigallocatechin-3-Gallate (Pro-EGCG) for the treatment of Endometriosis
NLS-1, a drug molecule derived from natural products (green tea), which is under development for the treatment of endometriosis, a disease in which the tissue that normally lines the uterus (endometrium) grows outside the uterus. It can grow on the ovaries, fallopian tubes, bowels, or bladder.
Its other products, which are under development includes: VLS-1: Curcumin-conjugated superparamagnetic iron oxide nanoparticles (Curcumin-MNP) for magnetic resonance imaging (MRI) imaging of amyloid beta plaques in Alzheimer’s disease (AD); VLS-2: mTOR-independent transcription factor EB activator (MITA) as autophagy activator for treatment of neurodegenerative diseases;
VLS-3: Novel retinal imaging agent for retinal imaging of amyloid plaques; VLS-4: Other contrast agents for MRI diagnostics; ALS-2: Small molecule for the treatment of bacterial infections caused by Staphylococcus aureus including MRSA; ALS-3: Small molecule acting synergistically with certain existing antibiotics; NLS-2: An extract from Chinese Yam for relief of menopausal symptoms; NLS-3: an extract from garlic for the treatment of and protection against retinal ischemia/reperfusion injury; and SLS-1: Robotic Catheter Platform for Intra-operative MRI-guided Cardiac Catheterization;
Aptorum Group Ltd
Guangdong Investment Tower, 148